{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:06:16Z","timestamp":1790057176904,"version":"4.0.1"},"reference-count":28,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2026.13272","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:46:00Z","timestamp":1786700760000},"page":"1-10","source":"Crossref","is-referenced-by-count":0,"title":["Integrating clinical outcomes with molecular simulations to guide the selection of non\u2011classical EGFR\u2011TKIs: A comprehensive analysis and development of treatment strategies"],"prefix":"10.3892","volume":"32","author":[{"given":"Fang","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niu","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Li","sequence":"additional","affiliation":[{"name":"School of Computer and Information, Hefei University of Technology, Hefei, Anhui 230009, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Gao","sequence":"additional","affiliation":[{"name":"School of Computer and Information, Hefei University of Technology, Hefei, Anhui 230009, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[{"name":"School of Computer and Information, Hefei University of Technology, Hefei, Anhui 230009, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"key20260922084559_b1-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: Mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"key20260922084559_b2-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-Mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"key20260922084559_b3-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"key20260922084559_b4-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.lungcan.2017.04.016","article-title":"Uncommon EGFR mutations in advanced non-small cell lung cancer","volume":"109","author":"O'Kane","year":"2017","journal-title":"Lung Cancer"},{"key":"key20260922084559_b5-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41586-023-05783-5","article-title":"The evolution of lung cancer and impact of subclonal selection in TRACERx","volume":"616","author":"Frankell","year":"2023","journal-title":"Nature"},{"issue":"20848","key":"key20260922084559_b6-ETM-32-4-13272","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48210-5","article-title":"Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib","volume":"13","author":"Yamaguchi","year":"2023","journal-title":"Sci Rep"},{"key":"key20260922084559_b7-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jtho.2024.03.016","article-title":"Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review","volume":"19","author":"Borgeaud","year":"2024","journal-title":"J Thorac Oncol"},{"key":"key20260922084559_b8-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.3390\/curroncol30060405","article-title":"Afatinib for the treatment of NSCLC with uncommon EGFR mutations: A narrative review","volume":"30","author":"Jiang","year":"2023","journal-title":"Curr Oncol"},{"issue":"103592","key":"key20260922084559_b9-ETM-32-4-13272","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103592","article-title":"Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: Retrospective Observational multicenter study (ARTICUNO)","volume":"9","author":"Pizzutilo","year":"2024","journal-title":"ESMO Open"},{"issue":"918855","key":"key20260922084559_b10-ETM-32-4-13272","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.918855","article-title":"Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18-18 and EGFR amplification: A case report","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"key20260922084559_b11-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00432-022-04033-x","article-title":"All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations","volume":"149","author":"Ullas","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"88","key":"key20260922084559_b12-ETM-32-4-13272","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-018-2093-6","article-title":"Prediction of sensitivity to gefitinib\/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis","volume":"19","author":"Zou","year":"2018","journal-title":"BMC Bioinformatics"},{"issue":"1832","key":"key20260922084559_b13-ETM-32-4-13272","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101832","article-title":"Implementation of artificial intelligence in personalized prognostic assessment of lung cancer: A narrative review","volume":"16","author":"Lococo","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"e000550","key":"key20260922084559_b14-ETM-32-4-13272","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000550","article-title":"Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker","volume":"8","author":"He","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"18935","key":"key20260922084559_b15-ETM-32-4-13272","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23649-0","article-title":"Machine learning based personalized drug response prediction for lung cancer patients","volume":"12","author":"Qureshi","year":"2022","journal-title":"Sci Rep"},{"issue":"5823","key":"key20260922084559_b16-ETM-32-4-13272","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225823","article-title":"Oligoprogression in non-small cell lung cancer","volume":"13","author":"Harada","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20260922084559_b17-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"28","author":"Jackman","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20260922084559_b18-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"issue":"1","key":"key20260922084559_b19-ETM-32-4-13272","doi-asserted-by":"publisher","DOI":"10.1186\/s41512-021-00115-5","article-title":"Performance of binary prediction models in high-correlation low-dimensional settings: A comparison of methods","volume":"6","author":"Leeuwenberg","year":"2022","journal-title":"Diagn Progn Res"},{"key":"key20260922084559_b20-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","article-title":"Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: A database of 693 cases","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"key20260922084559_b21-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.lungcan.2022.08.010","article-title":"Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients","volume":"172","author":"Wang","year":"2022","journal-title":"Lung Cancer"},{"key":"key20260922084559_b22-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20260922084559_b23-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20260922084559_b24-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","article-title":"Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions","volume":"8","author":"Oxnard","year":"2013","journal-title":"J Thorac Oncol"},{"key":"key20260922084559_b25-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"919652","key":"key20260922084559_b26-ETM-32-4-13272","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.919652","article-title":"Dacomitinib for advanced non-small cell lung cancer patients harboring major uncommon EGFR alterations: A dual-center, single-arm, ambispective cohort study in China","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"key20260922084559_b27-ETM-32-4-13272","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/curroncol29010024","article-title":"Uncommon EGFR compound mutations in non-small cell lung cancer (NSCLC): A systematic review of available evidence","volume":"29","author":"Attili","year":"2022","journal-title":"Curr Oncol"},{"issue":"1431","key":"key20260922084559_b28-ETM-32-4-13272","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061431","article-title":"Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario","volume":"20","author":"Russo","year":"2019","journal-title":"Int J Mol Sci"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:46:04Z","timestamp":1790055964000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2026.13272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,14]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2026.13272","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}